Fate Therapeutics starts potentially registrational RECLAIM-LN FT819 trial
Fate Therapeutics (FATE) initiates the potentially registrational RECLAIM-LN clinical trial of FT819 for the treatment of lupus nephritis.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.